Ubs Group Ag Pure Tech Health PLC Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Pure Tech Health PLC stock. As of the latest transaction made, Ubs Group Ag holds 1,903 shares of PRTC stock, worth $35,947. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,903

Previous 647 194.13%

Holding current value

$35,947

Previous $13,000 169.23%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$18.46 - $23.39 $23,185 - $29,377	1,256 Added 194.13%	1,903 $35,000
Q3 2024 Nov 14, 2024	BUY	$19.42 - $25.0 $5,748 - $7,400	296 Added 84.33%	647 $13,000
Q2 2024 Aug 13, 2024	BUY	$23.78 - $32.98 $7,871 - $10,916	331 Added 1655.0%	351 $8,000
Q4 2023 Feb 09, 2024	SELL	$17.08 - $28.18 $136 - $225	-8 Reduced 28.57%	20 $0
Q3 2023 Nov 09, 2023	BUY	$22.5 - $30.0 $180 - $240	8 Added 40.0%	28 $0
Q2 2023 Aug 11, 2023	SELL	$25.12 - $31.36 $25 - $31	-1 Reduced 4.76%	20 $0
Q1 2023 May 12, 2023	BUY	$24.93 - $35.25 $24 - $35	1 Added 5.0%	21 $0
Q3 2022 Nov 10, 2022	SELL	$20.71 - $31.5 $7,227 - $10,993	-349 Reduced 94.58%	20 $1,000
Q2 2022 Aug 10, 2022	BUY	$18.87 - $28.6 $6,585 - $9,981	349 Added 1745.0%	369 $7,000
Q3 2021 Nov 15, 2021	SELL	$43.2 - $53.44 $1,857 - $2,297	-43 Reduced 68.25%	20 $1,000
Q2 2021 Aug 13, 2021	SELL	$46.55 - $60.0 $3,072 - $3,960	-66 Reduced 51.16%	63 $3,000
Q1 2021 May 12, 2021	SELL	$49.78 - $64.0 $4,778 - $6,144	-96 Reduced 42.67%	129 $7,000
Q4 2020 Feb 11, 2021	BUY	$38.5 - $54.0 $8,662 - $12,150	225 New	225 $12,000

Others Institutions Holding PRTC

# of Institutions

Shares Held

373K

Call Options Held

Put Options Held

View Full List

About PureTech Health plc

Ticker PRTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,888,500
Market Cap $527M
Description
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholi...

More about PRTC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account